Przejdź do zawartości
Merck
Wszystkie zdjęcia(1)

Dokumenty

C0685000

Cefotaxime sodium

European Pharmacopoeia (EP) Reference Standard

Synonim(y):

Cefotaxime sodium salt, Cefotaxim sodium salt

Zaloguj sięWyświetlanie cen organizacyjnych i kontraktowych
Wszystkie zdjęcia(1)

About This Item

Wzór empiryczny (zapis Hilla):
C16H16N5NaO7S2
Numer CAS:
64485-93-4
Masa cząsteczkowa:
477.45
Beilstein:
5711411
Numer MDL:
MFCD00079073
Kod UNSPSC:
41116107
Identyfikator substancji w PubChem:
329774812
NACRES:
NA.24

klasa czystości

pharmaceutical primary standard

rodzina API

cefotaxime

producent / nazwa handlowa

EDQM

Zastosowanie

pharmaceutical (small molecule)

format

neat

ciąg SMILES

[Na+].[H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\c3csc(N)n3)C([O-])=O

InChI

1S/C16H17N5O7S2.Na/c1-6(22)28-3-7-4-29-14-10(13(24)21(14)11(7)15(25)26)19-12(23)9(20-27-2)8-5-30-16(17)18-8;/h5,10,14H,3-4H2,1-2H3,(H2,17,18)(H,19,23)(H,25,26);/q;+1/p-1/b20-9-;/t10-,14-;/m1./s1

Klucz InChI

AZZMGZXNTDTSME-JUZDKLSSSA-M

Szukasz podobnych produktów? Odwiedź Przewodnik dotyczący porównywania produktów

Powiązane kategorie

Opis ogólny

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Zastosowanie

Cefotaxime sodium EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Działania biochem./fizjol.

Cefotaxim inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls. As a result, bacteria lyse due to cell wall autolytic enzymes.

Opakowanie

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Inne uwagi

Broad spectrum third generation cephalosporin antibiotic.
Sales restrictions may apply.

Piktogramy

Health hazard
GHS08

Hasło ostrzegawcze

Danger

Zwroty wskazujące rodzaj zagrożenia

H317,H334

Zwroty wskazujące środki ostrożności

P261 - P280 - P284 - P304 + P340 - P333 + P313 - P342 + P311

Klasyfikacja zagrożeń

Resp. Sens. 1 - Skin Sens. 1

Kod klasy składowania

11 - Combustible Solids

Klasa zagrożenia wodnego (WGK)

WGK 2

Temperatura zapłonu (°F)

Not applicable

Temperatura zapłonu (°C)

Not applicable

Choose from one of the most recent versions:

Certyfikaty analizy (CoA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Obsługa Klienta

Masz już ten produkt?

Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.

Odwiedź Bibliotekę dokumentów

Klienci oglądali również te produkty

Slide 1 of 7

1 of 7

Cefoxitin sodium European Pharmacopoeia (EP) Reference Standard

C0688000

Cefoxitin sodium

Cefquinome sulfate VETRANAL®, analytical standard

Supelco

32472

Cefquinome sulfate

Ceftriaxone sodium European Pharmacopoeia (EP) Reference Standard

C0691000

Ceftriaxone sodium

Tazobactam sodium salt β-lactamase inhibitor

Sigma-Aldrich

T2820

Tazobactam sodium salt

Vancomycin hydrochloride European Pharmacopoeia (EP) Reference Standard

V0045000

Vancomycin hydrochloride

Cefoxitin sodium salt

Supelco

C4786

Cefoxitin sodium salt

Ceftazidime

Sigma-Aldrich

CDS020667

Ceftazidime

I Mounchetrou Njoya et al.
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 17(34) (2012-09-04)
In April 2012, a cluster of two cases of meningococcal disease caused by rifampicin-resistant C meningococci was reported in the Champagne-Ardenne region, France. The two cases occurred in a student population living in the same town but studying at different
Martijn F Schenk et al.
PLoS genetics, 8(6), e1002783-e1002783 (2012-07-05)
For a quantitative understanding of the process of adaptation, we need to understand its "raw material," that is, the frequency and fitness effects of beneficial mutations. At present, most empirical evidence suggests an exponential distribution of fitness effects of beneficial
Lakshmi Chandramohan et al.
Antimicrobial agents and chemotherapy, 56(9), 4765-4770 (2012-06-27)
Very little is known about the prevalence and composition of various types of extended-spectrum β-lactamases (ESBL) in pediatric patients. The aims of this study were the following: (i) to determine the prevalence of ESBLs among Enterobacteriaceae in a tertiary-care pediatric
Yidan Cui et al.
PloS one, 7(11), e48880-e48880 (2012-11-16)
Extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae poses serious challenges to clinicians because of its resistance to many classes of antibiotics. The mechanism of synergistic activity of a combination of (-)-epigallocatechin-3-gallate (EGCG) and β-lactam antibiotics cefotaxime was studied on Extended-spectrum β-lactamase producing Escherichia
Hetty Blaak et al.
International journal of food microbiology, 168-169, 8-16 (2013-11-12)
The attribution of fresh produce to the overall community-associated exposure of humans to ESBL- or AmpC-producing bacteria is currently unknown. To address this issue, the prevalence of ESBL- and AmpC-producing Enterobacteriaceae on fresh produce produced in the Netherlands was determined.
Wyświetl wszystkie powiązane dokumenty

Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.

Skontaktuj się z zespołem ds. pomocy technicznej